Compare CIVI & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIVI | TLX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.3B |
| IPO Year | 2011 | N/A |
| Metric | CIVI | TLX |
|---|---|---|
| Price | $27.19 | $8.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $40.80 | $21.00 |
| AVG Volume (30 Days) | ★ 1.4M | 165.5K |
| Earning Date | 11-06-2025 | 01-15-2026 |
| Dividend Yield | ★ 7.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 6.86 | 0.04 |
| Revenue | ★ $4,711,808,000.00 | $664,225,558.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $3.96 | $189.73 |
| Revenue Growth | N/A | ★ 55.35 |
| 52 Week Low | $22.79 | $7.72 |
| 52 Week High | $55.35 | $30.36 |
| Indicator | CIVI | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 42.21 | 33.56 |
| Support Level | $26.70 | $7.72 |
| Resistance Level | $28.28 | $10.03 |
| Average True Range (ATR) | 1.01 | 0.25 |
| MACD | -0.24 | -0.10 |
| Stochastic Oscillator | 14.03 | 16.45 |
Civitas Resources Inc is an independent exploration and production company engaged in the acquisition, development, and production of oil and associated liquids-rich natural gas in the Rocky Mountain region, in the Denver-Julesburg Basin of Colorado - DJ Basin. The company's operations are focused on developing the horizontal Niobrara and Codell formations that have a low-cost structure, mature infrastructure, production efficiencies, multiple producing horizons, multiple service providers, established reserves, and prospective drilling opportunities.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.